[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-sclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-sclc":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100612789",false,"NCT07258147","Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases","Clinical Study on the Efficacy and Safety of Radiotherapy Combined With Immunotherapy and Chemotherapy for Pre-treated Patients With Small Cell Lung Cancer and Liver Metastases","Inclusion Criteria:\n\n1. Aged 18 to 75 years, with an ECOG Performance Status of 0-2.\n2. Histologically confirmed stage IV non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer, with radiologically confirmed liver metastases (at least one measurable lesion with the longest diameter ≥ 1 cm).\n3. Prior failure (due to progression or intolerance) to platinum-based doublet chemotherapy and PD-1\u002FPD-L1 inhibitor therapy.\n4. Adequate liver function reserve (Child-Pugh class A or B, ALT\u002FAST ≤ 5 × ULN, total bilirubin ≤ 1.5 × ULN).\n5. Life expectancy of at least 3 months.\n6. Normal function of major organs and no severe dysfunction of the hematopoietic, cardiac, pulmonary, hepatic, renal, or bone marrow systems, or immunodeficiency diseases.\n7. Within one week prior to enrollment, bone marrow and organ function meet the following criteria:Hemoglobin ≥ 80 g\u002FL, neutrophil count ≥ 1.5 × 10⁹\u002FL, and platelet count ≥ 70 × 10⁹\u002FL. Renal function: Serum creatinine ≤ 1.5 × ULN, and endogenous creatinine clearance rate ≥ 55 ml\u002Fmin.Liver function: Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN (if liver metastases are present, total bilirubin ≤ 3 × ULN and transaminases ≤ 5 × ULN are acceptable).\n8. Voluntarily participates and provides written informed consent.\n9. Good compliance and willingness to adhere to the study visit schedule and other protocol requirements.\n10. Willingness to provide blood and tissue samples for biomarker testing.\n11. Judged by the radiation oncologist to have no contraindications to liver radiotherapy. Patients who agree to receive immunotherapy, chemotherapy, and radiotherapy.\n12. For patients of childbearing potential: agreement to use effective contraception during the study period and for at least 6 months after the last study treatment; negative serum or urine pregnancy test within 7 days prior to study entry; and not breastfeeding. Male patients with partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Presence of any active autoimmune disease or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism \\[may be included if controlled with hormone replacement therapy\\]); prior liver radiotherapy or liver transplantation; history of liver cirrhosis (Fibroscan ≥ F3), portal hypertension, or hepatic encephalopathy.\n2. Congenital or acquired immunodeficiency, such as Human Immunodeficiency Virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU\u002Fml), hepatitis C (positive HCV antibody and HCV RNA above the lower limit of detection of the assay), or co-infection with both hepatitis B and C.\n3. Uncontrolled or significant cardiac disease, including: (a) NYHA Class II or higher heart failure; (b) Unstable angina; (c) Myocardial infarction within the past 1 year; (d) Patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention.\n4. Severe infection or serious comorbidities within 4 weeks prior to the first dose of study treatment.\n5. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n6. History of other primary malignancies within the past 5 years.\n7. Known allergy to any of the trial drugs or their excipients.\n8. Pregnant or lactating women, or subjects of childbearing potential unwilling to use effective contraception during the study period.\n9. Patients with Child-Pugh class B or C liver insufficiency.\n10. Any other contraindication as determined by the investigator to preclude participation in the study.","ALL","18 Years","75 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is clinical trial evaluating the safety and efficacy of radiotherapy combined with immunotherapy and chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) and liver metastases.",[26],"Lung Cancer (SCLC)",[28,29,30,31],"SCLC","Radiotherapy","Immunotherapy","Chemotherapy","NOT_YET_RECRUITING","2026-05-04",{"date":35,"type":36},"2026-05-05","ACTUAL",{"date":38,"type":20},"2026-10-31",{"date":40,"type":20},"2028-12-30",{"name":42,"class":43},"Sichuan University","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100626950","NCT07442292","PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor","PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor","Inclusion Criteria:\n\n1. Aged 18-75, male and female, with ECOG score of 0 or 1;\n2. Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;\n3. underwent PD-L1 IHC examination before therapy;\n4. The expected survival was more than 26 weeks;\n5. Blood routine test, liver and kidney function meet the following standards: blood routine: WBC \\>= 4.0 x 10\\^9\u002FL or neutrophil \\>= 1.5 x 10\\^9\u002F:, PLT \\>= 100 x 10\\^9 \u002F L, Hb \\>= 90g \u002F L; Pt or APTT \\\u003C= 1.5 upper limit of normal value; liver and kidney function: total bilirubin \\\u003C= 1.5 x ULT (upper limit of normal value), ALT \u002F AST \\\u003C= 2.5 upper limit of normal value or \\\u003C= 5 x ULT (subject with liver metastasis), ALP \\\u003C= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP \\\u003C= 4.5 upper limit of normal value); BUN \\\u003C= 1.5 x ULT, SCR \\\u003C= 1.5 x ULT;\n6. According to RECIST1.1, there was at least one measurable target lesion;\n7. Understand and sign informed consent voluntarily with good compliance.\n\nExclusion Criteria:\n\n1. The function of liver and kidney was seriously abnormal;\n2. Preparation for pregnant, pregnant and lactating women;\n3. Inability to lie flat for half an hour;\n4. Suffering from claustrophobia or other mental disorders;\n5. Other researchers considered it unsuitable to participate in the trial.",{"count":52,"type":20},40,"OBSERVATIONAL","The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET\u002FCT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.",[56,26,57,58,59,60],"Lung Cancer (NSCLC)","Melanoma (Skin Cancer)","Melanoma Metastatic","PD-L1","PET \u002F CT","2026-03-03",{"date":63,"type":36},"2026-03-05",{"date":65,"type":20},"2026-02",{"date":67,"type":20},"2027-06",{"name":69,"class":43},"Peking University Cancer Hospital & Institute",""]